Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 10:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 757 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Active then Sham Treatment Clear all
Completed Phase 3 Interventional Results available

The Effects of Wellbutrin (Bupropion) on Residual and Cognitive Symptoms in SSRI-treated Depression

NCT00125957
View directory record Official record
Conditions
Depression, Major Depressive Disorder, Unipolar Depression
Interventions
Wellbutrin, Placebo
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 6, 2014 · Synced Oct 15, 2026, 10:54 AM EDT
Recruiting Phase 2 Interventional

Prevention/Reduction of ASRs and PTSD to Sustain Civilian Performance With Sublingual Cyclobenzaprine HCl (TNX-102 SL)

NCT06636786
View directory record Official record
Conditions
Acute Stress Reaction, Acute Stress Disorder, Neurocognitive Function, Post-traumatic Stress
Interventions
Cyclobenzaprine HCl, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 55 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
9
States / cities
Birmingham, Alabama • Indianapolis, Indiana • Kansas City, Kansas + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 15, 2026, 10:54 AM EDT
Completed Not applicable Interventional Results available

Effect of rTMS on Resting State Brain Activity in Tinnitus

NCT00926237
View directory record Official record
Conditions
Tinnitus
Interventions
Sham rTMS - Sham repetitive transcranial magnetic stimulation, Active 1 Hz rTMS - Active repetitive transcranial magnetic stimulation delivered at 1 Hz frequency, Active 10 Hz rTMS - active repetitive transcranial magnetic stimulation delivered at 10 Hz frequency
Device
Lead sponsor
University of Arkansas
Other
Eligibility
19 Years to 89 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Nov 20, 2020 · Synced Oct 15, 2026, 10:54 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Maximizing the Impact of Neuroplasticity Using Transcranial Electrical Stimulation Study 1

NCT03896425
View directory record Official record
Conditions
Transcranial Direct Current Stimulation, Healthy
Interventions
Transcranial direct current stimulation (tDCS)
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 60 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 7, 2024 · Synced Oct 15, 2026, 10:54 AM EDT
Not yet recruiting Phase 2 Interventional

Nicotinamide Riboside Supplementation in Chronic Kidney Disease

NCT07693543
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Nicotinamide Riboside (NR), Matched Placebo (Capsules)
Dietary Supplement
Lead sponsor
University of California, San Diego
Other
Eligibility
30 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 15, 2026, 10:54 AM EDT
Completed Phase 2 Interventional Results available

A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Nephritis

NCT01085097
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Laquinimod, Mycophenolate Mofetil, Prednisolone/Prednisone, Placebo, Methylprednisolone
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
14
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Oct 15, 2026, 10:54 AM EDT
Suspended Phase 1Phase 2 Interventional

Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1

NCT06071767
View directory record Official record
Conditions
HIV-1-infection
Interventions
ChAdOx1.tHIVconsv1, ChAdOx1.HIVconsv62, MVA.tHIVconsv3, MVA.tHIVconsv4, Vesatolimod (VES), GS-5423, GS-2872, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
9
States / cities
San Diego, California • Atlanta, Georgia • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 15, 2026, 10:54 AM EDT
Withdrawn Phase 3 Interventional

Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP)

NCT05061771
View directory record Official record
Conditions
Bullous Pemphigoid
Interventions
nomacopan (rVA576), Placebo
Drug · Other
Lead sponsor
AKARI Therapeutics
Industry
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
7
States / cities
Los Angeles, California • Skokie, Illinois • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Oct 15, 2026, 10:54 AM EDT
Completed Phase 3 Interventional Results available

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

NCT01377012
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Secukinumab (AIN457), Placebo
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
39
States / cities
Mesa, Arizona • Paradise Valley, Arizona • Peoria, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 15, 2026, 10:54 AM EDT
Completed Phase 3 Interventional Results available

A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) With an Inadequate Response or Intolerance to Biologic DMARDs

NCT02706847
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo, Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
103
States / cities
Huntsville, Alabama • Mesa, Arizona • Phoenix, Arizona + 85 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 15, 2026, 10:54 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Brain as a Therapeutic and Research Target in Trigeminal Neuropathic Pain

NCT03003715
View directory record Official record
Conditions
Trigeminal Neuropathic Pain
Interventions
PET Scans, transcranial direct current stimulation (tDCS), MRI, sham tDCS (prior to real tDCS)
Procedure · Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 24, 2017 · Synced Oct 15, 2026, 10:54 AM EDT
Active, not recruiting Phase 3 Interventional

Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

NCT04498117
View directory record Official record
Conditions
Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Fallopian Tube Neoplasms, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Peritoneal Cancer, Peritoneal Carcinoma, Peritoneal Neoplasms
Interventions
Oregovomab, Paclitaxel, Carboplatin, Placebo
Biological · Drug
Lead sponsor
CanariaBio Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
615 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
81
States / cities
Phoenix, Arizona • Tucson, Arizona • Concord, California + 70 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 15, 2026, 10:54 AM EDT
Completed Phase 2 Interventional Results available

Adaptive Pharmacotherapy for Smoking Cessation

NCT02501265
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Varenicline Standard Protocol, Nicotine Patch Standard Protocol, Varenicline Adaptive Protocol, Nicotine Adaptive Protocol
Behavioral · Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 19, 2021 · Synced Oct 15, 2026, 10:54 AM EDT
Terminated Not applicable Interventional

Guided Imagery and Transcranial Direct Current Stimulation (tDCS) in Women With Chronic Pelvic Pain

NCT02781103
View directory record Official record
Conditions
Cystitis, Interstitial, Pelvic Pain
Interventions
Guided imagery plus active tDCS, Guided imagery plus Sham tDCS
Other
Lead sponsor
Kenneth M Peters, MD
Other
Eligibility
18 Years to 64 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Oct 15, 2026, 10:54 AM EDT
Active, not recruiting Phase 2 Interventional

A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis

NCT07105488
View directory record Official record
Conditions
Atopic Dermatitis (AD)
Interventions
BFB759, Placebo
Biological · Drug
Lead sponsor
Bluefin Biomedicine, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
48
States / cities
Phoenix, Arizona • Encino, California • Huntington Beach, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 15, 2026, 10:54 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Treating Depression With Transcranial Direct Current Stimulation (tDCS)

NCT00481988
View directory record Official record
Conditions
Depression
Interventions
transcranial direct current stimulation, iomed phoresor transcranial direct current stimulation
Device
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 20, 2013 · Synced Oct 15, 2026, 10:54 AM EDT
Completed Phase 2 Interventional Results available

A Study Investigating Long-term Treatment With Spesolimab in People With a Skin Disease Called Hidradenitis Suppurativa Who Completed a Previous Clinical Trial

NCT04876391
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Spesolimab 1200 mg, Spesolimab 600 mg, Placebo matching 600 mg Spesolimab, Placebo matching 1200 mg Spesolimab
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
4
States / cities
Los Angeles, California • Indianapolis, Indiana • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 15, 2026, 10:54 AM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Topical Cannabidiol Cream and Post-exercise Recovery

NCT05044936
View directory record Official record
Conditions
Muscle Damage
Interventions
Cannabidiol Oil, Resistance Exercise
Drug · Other
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 35 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated May 17, 2023 · Synced Oct 15, 2026, 10:54 AM EDT
Terminated Phase 3 Interventional Results available

Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (Core and Extension Phases)

NCT00549757
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Cardiovascular Disease
Interventions
Aliskiren, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
35 Years and older
Enrollment
8,606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
118
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 99 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 15, 2026, 10:54 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

The Revitalize Study in Older Adults at Risk for Alzheimer's Disease

NCT04018092
View directory record Official record
Conditions
Cognitive Aging, Alzheimer Disease, Protection Against
Interventions
Active NIR-PBM, Sham NIR-PBM
Device
Lead sponsor
University of Florida
Other
Eligibility
65 Years to 89 Years
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
2
States / cities
Tucson, Arizona • Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 15, 2026, 10:54 AM EDT
Completed Not applicable Interventional Results available

Transcranial Direct Current Stimulation and Cognitive Remediation Therapy for Psychosis

NCT02085421
View directory record Official record
Conditions
Psychosis
Interventions
tDCS
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 64 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Oct 15, 2026, 10:54 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease

NCT02877134
View directory record Official record
Conditions
Crohn Disease
Interventions
JNJ-64304500, Placebo, Ustekinumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
37
States / cities
Lone Tree, Colorado • Coral Gables, Florida • Kissimmee, Florida + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 15, 2026, 10:54 AM EDT
Terminated Phase 4 Interventional

Memantine or Riluzole Prophylaxis for Corticosteroid-induced Mood and Declarative Memory Changes

NCT00283309
View directory record Official record
Conditions
Mood, Memory Deficit
Interventions
Memantine, Riluzole
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2013 · Synced Oct 15, 2026, 10:54 AM EDT
Not listed Not applicable Interventional

Effects Of Osteopathic Manipulative Medicine(OMM) On Lower Extremity Muscle Characteristics In Parkinson's Disease(PD) Patients

NCT05884944
View directory record Official record
Conditions
Parkinson Disease, Osteopathy in Diseases Classified Elsewhere
Interventions
Sham- Light touch, not reaching restrictive barrier, Experimental: Interventional Group- OMM- Muscle energy
Procedure
Lead sponsor
New York Institute of Technology
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Old Westbury, New York
Source: ClinicalTrials.gov public record
Updated Aug 7, 2024 · Synced Oct 15, 2026, 10:54 AM EDT